BMFPs, a versatile therapeutic tool for redirecting a preexisting Epstein-Barr virus antibody response toward defined target cells.
Benoît Gamain1, Carine Brousse1, Nathan E. Rainey1, Béré K. Diallo2, Clara-Eva Paquereau1, Alexandra Desrames1, Jolita Ceputyte1, Jean-Philippe Semblat1, Olivier Bertrand1, Stéphane Gangnard1, Jean-Luc Teillaud2, Arnaud Chêne1*
1 University of Paris, Integrated Biology of the Red Blood Cell, UMR_S1134, Inserm, F-75015 Paris, France.
2 “Immune Microenvironment and Immunotherapy” Laboratory, Inserm U.1135, Center for Immunology and Infectious Diseases (CIMI-Paris), Faculty of Medicine, Sorbonne University, 91 boulevard de l’Hôpital, 75013 Paris, France.
Science Advances, February 11, 2022
DOI: 10.1126 / sciadv.abl4363
